Form 8-K - Current report:
SEC Accession No. 0000950170-22-011697
Filing Date
2022-06-15
Accepted
2022-06-15 17:08:24
Documents
12
Period of Report
2022-06-15
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K glue-20220615.htm   iXBRL 8-K 78251
  Complete submission text file 0000950170-22-011697.txt   205554

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT glue-20220615.xsd EX-101.SCH 2471
3 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT glue-20220615_pre.xml EX-101.PRE 11465
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT glue-20220615_lab.xml EX-101.LAB 17332
6 EXTRACTED XBRL INSTANCE DOCUMENT glue-20220615_htm.xml XML 4889
Mailing Address 645 SUMMER STREET SUITE 102 BOSTON MA 02210
Business Address 645 SUMMER STREET SUITE 102 BOSTON MA 02210 617-949-2643
Monte Rosa Therapeutics, Inc. (Filer) CIK: 0001826457 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40522 | Film No.: 221018490
SIC: 2836 Biological Products, (No Diagnostic Substances)